New treatments for chronic urticaria

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Chronic urticaria (CU) is a common, debilitating skin condition requiring improved therapeutic options beyond standard antihistamines and omalizumab.
• Current treatments for CU, while effective for some, leave a significant unmet need for alternative and advanced therapies.

Purpose of the Study:

• To review the current landscape of chronic urticaria (CU) treatments, including off-label uses of approved drugs.
• To highlight novel therapeutic agents currently under development for CU.
• To identify promising molecular targets for future CU drug discovery.

Main Methods:

• A comprehensive literature search of MEDLINE was conducted for recent treatment reports and targets in CU.
• ClinicalTrials.gov was searched for ongoing and recent randomized clinical trials in CU.
• Relevant studies were selected and critically reviewed.

Main Results:

• Omalizumab shows potential for expanded use in pediatric chronic spontaneous urticaria (CSU) and chronic inducible urticaria.
• Off-label use of biologics like dupilumab, reslizumab, mepolizumab, and benralizumab demonstrates efficacy in CU.
• Novel agents including ligelizumab, UB-221, chemoattractant receptor antagonists, Siglec-8 antibodies, and tyrosine kinase inhibitors are in development, targeting pathways like Mas-related G-protein-coupled receptor X2 and histamine 4 receptor.

Conclusions:

• There is a critical need for novel and improved treatments for chronic urticaria (CU).
• Several promising agents are in clinical trials, with more expected to emerge targeting newly identified pathways.
• Continued research into novel targets and therapies is crucial for advancing CU management.